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Drug  therapy  for  mild-to-moderate  hypertension 
during  pregnancy  is  generally  not  recommended  for  a 
blood pressure ≤ 149/95 mmHg [3]. Both hypertensive 
disorders  and  antihypertensive medication  use  in  early 
pregnancy  have  been  suggested  to  directly  affect  fetal 
development, and numerous studies have explored whe-
ther the prevalence of specific birth defects may be incre-




the  incidence  of  neonatal  outcomes  [5].  Severe  hyper-
tension  should  be  treated with  antihypertensive  drugs: 
methyldopa  and  labetalol  are  considered  the  drugs  of 
choice,  whereas  nifedipine  is  suggested  as  second-line 
therapy [3, 6]. The use of angiotensin-converting enzyme 
(ACE)  inhibitors  and  angiotensin  II  receptor  blockers 
(ARBs)  is  contraindicated during pregnancy  [3,  6]  be-
cause of the association with adverse fetal outcomes such 
as intrauterine growth retardation, neonatal hypotension, 
oligohydramnios,  and  patent  ductus  arteriosus  [7,  8]. 
Also diuretics should no longer be considered for the tre-
atment of hypertension because they can cause placental 




  Many  observational  studies  investigated  the  cha-
racteristics  of  drug  use  during  pregnancy,  but  only  a 
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Our  study  aimed  to  assess  if  the European Society 
of  Hypertension  &  European  Society  of  Cardiology 
(ESH-ESC) guidelines on  the use of antihypertensive 
drugs in pregnancy are followed in clinical practice. In 
particular,  we  estimated  the  proportion  of  pregnant 
women  who  are  treated  with  non-recommended  an-
tihypertensives.  We  also  assessed  whether  individual 




Definition of the study population






















Definition of the pregnancy period
The  pregnancy  onset  was  estimated  by  subtracting 
the gestational age (weeks of amenorrhea, as reported 























on  the prescriptions  issued  to outpatients by General 
Practitioners and covered by the NHS. For each pre-
scription,  the  following  information  is  available  at  re-
gional  level:  patient  code,  date  of  prescription,  drug 
authorization code and number of packages. No infor-
mation  is  available on prescriptions  issued during  the 
hospitalization.
We used the clinical investigation database to obtain 
information  on  women  presenting  chronic  diseases 
(such as diabetes, hypertension or epilepsy).
Therapeutic classes of antihypertensive drugs
The  antihypertensive  medications  were  classified 
as  recommended  and  non-recommended  during  pre-
gnancy according to the classification of the ESH-ESC 
guidelines  [3].  Methyldopa  (Anatomical  Therapeu-
tic  Chemical  classification  system,  ATC:  C02AB01), 
labetalol  (ATC:  C07AG01)  and  the  dihydropyridine 
calcium channel blocker nifedipine  (ATC: C08CA05) 
belong  to  the  recommended  medicines  group.  All 
the  other  antihypertensives  were  not  recommended; 
among  these  the  following  categories were  examined: 
ACE  inhibitors  (ATC:  C09A),  ARBs  (ATC:  C09C), 
diuretics  (ATC:  C03A,  C03B,  C03C,  C03D),  other 
β-blockers  (ATC: C07AA, C07AB) and combinations 
of  antihypertensive  substances  (ATC: C07B, C07CA, 
C07CB, C09BA, C09BB, C09D, C03E, C02LA).






Women  who  received  at  least  one  prescription  of 





gnancy, we  classified women  as  exposed  to  either  re-




pregnancy  received  at  least  1  prescription  of  non-re-
commended medications at any time during pregnancy. 
A  further evaluation was conducted on  incident users 




Prevalent  users,  new  users  and  unexposed  women 
were described on the basis of socio-demographic fac-
tors (age, marital status, socio-economic variables) and 
pregnancy  history  (previous  deliveries  and  previous 
cesarean  sections).  Prevalent  and  incident  users were 
compared through χ2 test for categorical variables. The 
number  of  hospitalizations  that  occurred  in  the  pre-
vious  year,  history of  selected  comorbidities,  and me-
































mothers;  socio-economic  status;  history  of  previous 
pregnancy(ies);  history  of  selected  comorbidities  and 
medications  at pregnancy onset  and health  care utili-
zation. Details on the specific confounders included in 








Age,  nationality,  socio-economic  factors  and  health 
status of women in the study cohort were also investiga-
ted as possible determinants of the use of non-recom-









The  study  cohort  included  86  171  women,  1009 
(1.2%) of whom were exposed to antihypertensive me-
dications  during  pregnancy:  334  (33.1%) were  preva-
lent users and 675 (66.9%) were new (incident) users 











Pattern of antihypertensive drug use and comparison 
with clinical guidelines recommendations
In the cohort, the prevalence of use, decreased from 
0.8% (n = 686) in the pre-gestational period to 0.3% (n 
= 280) during  the first  trimester and 0.2% during  the 
second (n = 176) and the third trimester (n = 186) of 

















Deliveries in the Lombardy region





• 793 Non resident in the Lombardy region
• 1455 Multiple birth
• 261 Deliveries  with gestational ages ≤  22 and > 45 weeks
• 2 Pregnant women aged  > 55
• 94 Pandemic vaccination prior to pregnancy onset
• 60 Congenital viral infections
• 98 Chromosomal anomalies
Figure 1
Flow-chart of women included in the study population. Users were classified as prevalent or incident users according to the begin-
ning of the exposure to antihypertensive drugs (before or during pregnancy, respectively).

























Baseline characteristics of the study population by use of antihypertensive drugs during pregnancy
Use of antihypertensive drugs during 
pregnancy
N = 1009 (1.2%)
P value
No use of antihypertensive 
drugs during pregnancy 
N = 85 162 (98.8%)Prevalent 
users 
N = 334 (0.4%)
New 
users 
N = 675 (0.8%)
Age group
≤ 34 131 (39.2) 395 (58.5) 57 477  (67.5)
35-39 140 (41.9) 212 (31.4) < 0.001 22 551  (26.5)
≥ 40 63 (18.9) 68 (10.1) 5134  (6.0)
Nationality
Italian 247 (74.0) 505 (74.8) 60 792 (71.4)
Not Italian 87 (26.0) 170 (25.2) 0.76 24 358 (28.6)
Not reported - - - - 12 (0.01)
Study degree
Elementary school/none   9 (2.7) 15 (2.2) 1905 (2.2)
Primary school 116 (34.7) 225 (33.4) 0.88 23 489 (27.6)
High school 141 (42.2) 302 (44.7) 37 178 (43.7)
University degree 62 (18.6) 127 (18.8) 21 622 (25.4)
Not reported 6 (1.8) 6 (0.9) 968 (1.1)
Occupational status
Employed 250 (74.9) 477 (70.7) 58 830 (69.1)
Unemployed/seeking first occupation 12 (3.6) 25 (3.7) 3759 (4.4)
Student/other 1 (0.3) 7 (1.0) 0.45 813 (0.9)
Housewife 70 (21.0) 161 (23.9) 21 558  (25.3)
Not reported 1 (0.2) 5 (0.7) 202 (0.3)
Civil status
Single 64  (19.2) 169 (25.0) 19 242 (22.6)
Married 246  (73.7) 452 (67.0) 0.09 61 525 (72.2)
Separated/divorced/widow 14 (4.2) 28 (4.1) 2633 (3.1)
Not declared/not reported 10 (2.9) 26 (3.9) 1762 (2.1)
Previous delivery(ies)
Yes 183 (54.8) 296 (43.9) 0.001 38 600 (45.3)
No 151 (45.2) 379 (56.1) 46 562 (54.7)
Previous cesarean delivery(ies)
Yes 58 (17.4) 89 (13.2) 0.07 9004 (10.6)
No 276 (82.6) 586 (86.8) 76 158 (89.4)
Number of comorbidities and medications used in the pregestational period
0 134 (40.1) 326 (48.3) 54 355 (63.8)
1-3 192 (57.5) 337 (49.9) 0.04 30 162 (35.4)
> 3 8  (2.4) 12 (1.8) 645 (0.8)
Hospital admissions in the last year
0 245 (73.4) 549 (81.3) 70 200 (82.4)
1-3 85 (25.4) 121 (17.9) 0.01 14 701 (17.3)
> 3 4  (1.2) 5 (0.7) 261 (0.3)


























with  other  antihypertensive):  the  proportion  of  users 
of  these  drugs  was  equal  to  18.6%  and  11.8%  in  the 
first trimester of pregnancy and decreased to 5.4% and 
1.1% in the third trimester  (Supplementary material 2). 
The  exposure  to  β-blockers  (excluding  labetalol)  also 
decreased,  from 24.3%  in  the first  trimester  to 13.1% 
and  13.4%  in  the  second  and  third  trimester,  respec-
tively. The proportion exposed to recommended drugs 
increased  from 38.6%  (n = 108)  in  the first  trimester 
to 73.7%  (n = 137)  in  the  third  trimester: dihydropy-
ridine calcium antagonists accounted for 28.9% of the 
exposure  in  the first  trimester  and 47.3%  in  the  third 
trimester  (Figure 2a). The  increase  in  the exposure  to 
methyldopa was even more evident (from 10.4% in the 






pregnancy,  showed  a  limited  reduction  in  the  use  of 
non-recommended drugs  in  the first  trimester of pre-
gnancy (from 61.4% to 53.0%, Supplementary material 3, 
available online at www.iss.it).



















of  β-blockers  and  ACE  inhibitors  was  halved  by  the 




Association between socio-demographic factors and 




ted with  higher  probability  of  receiving  a  non-recom-
mended therapy (Table 2). This risk increased with the 
number  of  comorbidities,  reaching  its  maximum  for 
women  with  at  least  four  concomitant  diseases  (OR 
= 2.68;  95% CI 1.10  to 6.73). Age, nationality,  study 
degree,  occupational  status  and  medical  history  (e.g. 
previous  deliveries,  previous  caesarean  sections  and 
number of hospitalizations in the year before pregnancy 










not  show relevant differences when  the first  six weeks 
of pregnancy were removed from the analysis. Although 













































a) Proportion of prevalent users exposed to recommended and 
non-recommended drugs by trimester of pregnancy.
b) Proportion of incident users exposed to recommended and 
non-recommended drugs (incident prescription) by trimester 
of pregnancy. 






























a  few articles  reporting on  the use of antihypertensive 
drugs  in  pregnancy.  Our  study  estimated  that  only  a 
limited  proportion  of  women  (1.2%) were  exposed  to 


















Association between socio-demographic and health factors and the treatment with non-recommended drugs during pregnancy
Women exposed to antihypertensive 












Age group at delivery
≤ 34 208 318 Ref. Ref.
35-39 148 204 1.11 0.84-1.46 1.08 0.82-1.43
≥ 40 56 75 1.14 0.77-1.68 1.13 0.76-1.66
Nationality
Italian 306 446 Ref. Ref.
Not Italian 106 151 1.02 0.77-1.36 1.02 0.77-1.36
Study degree
Other study degree 336 472 Ref. Ref.
University degree 70 119 0.83 0.60-1.15 0.83 0.60-1.16
Not reportedb 6 6 - - - -
Occupational status
Employed 303 424 Ref. Ref.
Unemployed 108 168 0.90 0.68-1.19 0.91 0.69-1.21
Not reportedb 1 5
Previous delivery(ies)
No 213 317 Ref. Ref.
Yes 199 280 1.06 0.82-1.36 1.06 0.83-1.37
Previous cesarean delivery(ies)
No 353 509 Ref. Ref.
Yes 59 88 0.97 0.68-1.38 0.97 0.68-1.39
Number of comorbidities and medications in the pregestational period
0 165 295 Ref.
1 133 187 1.27 0.95-1.71
2 75 78 1.72 1.18-2.50
3 27 29 1.66 0.95-2.91
≥ 4 12 8 2.68 1.10-6.73
Hospital admissions in the last year
0 325 469 Ref.
≥ 1 87 128 0.98 0.72-1.33 0.90 0.66-1.23
aOR adjusted for number of comorbidities and medications in the pregestational period.
bNot reported data were not considered in the analysis.


















































other  than  labetalol  were  widely  represented  in  our 
cohort; in particular, atenolol, bisoprolol and nebivolol 







observed  in  our  study  are  reproducible.  The  content 
of  the ESH-ESC guidelines  is widely  shared by other 
guidelines [2,6], and an Italian translation was available 
[21]. Moreover,  similar  recommendations were  inclu-
ded  in a handbook on  the use of drugs  in pregnancy, 
which was promoted by the Italian Medicines Agency 
and distributed  in  2004  to  all  Italian physicians  [22]. 
About  half  of  the  patients  taking  antihypertensive 
drugs during the pre-gestational period interrupted the 




overestimation of  the  teratogenic  risk  associated with 
the use of drugs during pregnancy [23].
A major strength of our study is the capability to take 
into  account  the  role  of  many  potential  confounders 
(including  socio-economic  status)  which  were  identi-
fied through the use of multiple databases. The study 
design was based on registry-collected information and 
consequently  the  classification  of  exposure  was  inde-
pendent from the selection of confounding factors and 
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